These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21315731)

  • 1. Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection.
    Ciupe SM; De Leenheer P; Kepler TB
    J Theor Biol; 2011 May; 277(1):55-66. PubMed ID: 21315731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricted occupancy models for neutralization of HIV virions and populations.
    Magnus C; Regoes RR
    J Theor Biol; 2011 Aug; 283(1):192-202. PubMed ID: 21683711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.
    Tudor D; Bomsel M
    AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
    Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
    Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study describes onset of broadly neutralizing antibody responses in HIV-infected individuals.
    von Bubnoff A
    IAVI Rep; 2011; 15(1):23. PubMed ID: 21449508
    [No Abstract]   [Full Text] [Related]  

  • 11. A mathematical model of HIV infection: Simulating T4, T8, macrophages, antibody, and virus via specific anti-HIV response in the presence of adaptation and tropism.
    Wasserstein-Robbins F
    Bull Math Biol; 2010 Jul; 72(5):1208-53. PubMed ID: 20151219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
    Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
    Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution.
    Costers S; Vanhee M; Van Breedam W; Van Doorsselaere J; Geldhof M; Nauwynck HJ
    Virus Res; 2010 Dec; 154(1-2):104-13. PubMed ID: 20837070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
    Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
    Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
    Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H
    Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
    Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.